Immunitybio announces positive overall survival results of anktiva combined with checkpoint inhibitors in non-small cell lung cancer; meeting scheduled with fda to discuss registration path for anktiva in lung cancer

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), an immunotherapy company, today announced positive overall survival results in the quilt 3.055 study of 2nd- and 3rd-line nsclc patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy to be discussed during the upcoming conference call. the results continue to reinforce immunitybio's belief in the unique mechanism of action of anktiva (n-803, o.
IBRX Ratings Summary
IBRX Quant Ranking